Mandate

Vinge advises Vostok New Ventures Ltd

February 25, 2019 Capital Markets and Public M&A

Vinge has advised Vostok New Ventures Ltd with capital markets related questions in light of the company’s divestment of its portfolio asset Avito, for in total USD 540 million, equivalent of approximately SEK 4,842 million, as well as in connection with the subsequent split and mandatory redemption program whereby each depository receipt holder (“SDRs”) will receive a cash consideration of SEK 25 per SDR.

In total, the company will redeem approximately 81,000,000 SDRs for a cash consideration amount of approximately SEK 2 billion. 

The redemption procedure was approved by a special general meeting in Vostok New Ventures on 14 February 2019. The redemption SDRs will be traded on Nasdaq Stockholm during the period 22 February – 7 March 2019.

Vinge’s team primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Annika Nyberg Ekenberg, Henrik Wastenson and Emelie Svanberg.
 

Related

Vinge advises Revivo Group on the acquisition of Premator

Revivo Group AB has acquired all the shares in Premator AB, the parent company of a group operating in the field of advanced surface treatment with extensive experience in shot blasting, anti-corrosion painting and related services. Operations are conducted in Sweden, Norway and Denmark.
September 03, 2026

Vinge advises the sellers of Berg Propulsion

Vinge has advised the sellers in connection with the sale of Berg Propulsion to Kongsberg Maritime.
September 03, 2026

Vinge advises the sellers on the sale of Nextory to Bonnier Books

Vinge has acted as legal adviser to the sellers in connection with Bonnier Books’ acquisition of Nextory, one of Europe’s leading streaming services for audiobooks and e-books. Bonnier Books is acquiring all shares in Nextory, and the transaction comprises Nextory’s operations in Sweden and internationally. The acquisition is a cash transaction and the parties have agreed not to disclose the purchase price. The transaction is subject to customary regulatory approvals.
September 02, 2026